ES2347574T3 - Compuestos de arn de doble hebra especificos de vglut. - Google Patents
Compuestos de arn de doble hebra especificos de vglut. Download PDFInfo
- Publication number
- ES2347574T3 ES2347574T3 ES05707623T ES05707623T ES2347574T3 ES 2347574 T3 ES2347574 T3 ES 2347574T3 ES 05707623 T ES05707623 T ES 05707623T ES 05707623 T ES05707623 T ES 05707623T ES 2347574 T3 ES2347574 T3 ES 2347574T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- sirna
- dna
- vglut2
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004011687 | 2004-03-10 | ||
| DE102004011687A DE102004011687A1 (de) | 2004-03-10 | 2004-03-10 | VGLUT-spezifische dsRNA-Verbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2347574T3 true ES2347574T3 (es) | 2010-11-02 |
Family
ID=34960530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05707623T Expired - Lifetime ES2347574T3 (es) | 2004-03-10 | 2005-02-24 | Compuestos de arn de doble hebra especificos de vglut. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070117771A1 (de) |
| EP (1) | EP1723234B1 (de) |
| AT (1) | ATE471375T1 (de) |
| DE (2) | DE102004011687A1 (de) |
| ES (1) | ES2347574T3 (de) |
| PL (1) | PL1723234T3 (de) |
| WO (1) | WO2005090571A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10356113A1 (de) | 2003-11-27 | 2005-06-23 | Behr Gmbh & Co. Kg | Verfahren zur Herstellung eines Werkstücks |
| CN112760276A (zh) * | 2021-03-24 | 2021-05-07 | 扬州大学 | 一种柑橘原生质体的制备方法 |
| CN114457045B (zh) * | 2022-02-25 | 2023-07-14 | 中国人民解放军军事科学院军事医学研究院 | 抑制Slc2a1的RNAi腺相关病毒及其制备和应用 |
| CN120366312A (zh) * | 2025-06-24 | 2025-07-25 | 南京农业大学三亚研究院 | 一种用于防治二化螟的靶向囊泡型谷氨酸转运体的dsRNA制剂与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002008384A2 (en) * | 2000-07-25 | 2002-01-31 | The Regents Of The University Of California | Novel glutamate transporters |
| DE10128541A1 (de) * | 2001-06-13 | 2003-02-20 | Gruenenthal Gmbh | Screening-Verfahren mit BNPI und DNPI |
| DE10133915A1 (de) * | 2001-07-12 | 2003-02-06 | Aventis Pharma Gmbh | Neue Oligoribonucleotid-Derivate zur gezielten Hemmung der Genexpression |
-
2004
- 2004-03-10 DE DE102004011687A patent/DE102004011687A1/de not_active Withdrawn
-
2005
- 2005-02-24 PL PL05707623T patent/PL1723234T3/pl unknown
- 2005-02-24 AT AT05707623T patent/ATE471375T1/de active
- 2005-02-24 DE DE502005009757T patent/DE502005009757D1/de not_active Expired - Lifetime
- 2005-02-24 EP EP05707623A patent/EP1723234B1/de not_active Expired - Lifetime
- 2005-02-24 ES ES05707623T patent/ES2347574T3/es not_active Expired - Lifetime
- 2005-02-24 WO PCT/EP2005/001970 patent/WO2005090571A1/de not_active Ceased
-
2006
- 2006-09-11 US US11/518,284 patent/US20070117771A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1723234A1 (de) | 2006-11-22 |
| DE502005009757D1 (de) | 2010-07-29 |
| DE102004011687A1 (de) | 2005-10-13 |
| US20070117771A1 (en) | 2007-05-24 |
| WO2005090571A1 (de) | 2005-09-29 |
| ATE471375T1 (de) | 2010-07-15 |
| PL1723234T3 (pl) | 2010-11-30 |
| EP1723234B1 (de) | 2010-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6845589B2 (ja) | 腱治癒を調節するための物質および方法 | |
| US20110165227A1 (en) | Compositions and Methods Using siRNA Molecules for Treatment of Gliomas | |
| US8163709B2 (en) | TAK1-D mediated induction of cell death in human cancer cells by specific sequence short double-stranded RNAS | |
| JP2017536826A (ja) | 幹細胞および/または前駆細胞からの赤血球産生を改善するためのsh2b3の調節 | |
| Simmons et al. | Retroviral transduction of T cells and T cell precursors | |
| WO2017062659A1 (en) | Compositions and methods for treating diabetic retinopathy | |
| CN103380214B (zh) | 用于治疗脑肿瘤的支链氨基转移酶-1(bcat1)抑制剂 | |
| US20070117771A1 (en) | VGLUT-specific dsRNA compounds | |
| ES2559106B1 (es) | Método de activación de la expresión del gen Pitx2 para promover la regeneración muscular | |
| CN101213300B (zh) | 用于rna干扰的寡核苷酸及其生物学应用 | |
| CA2672937A1 (en) | Inhibitory polynucleotide compositions and methods for treating cancer | |
| AU2009303355B2 (en) | FAS/FASL or other death receptor targeted methods and compositions for killing tumor cells | |
| US20150299712A1 (en) | Modulation of Hematopoietic Stem Cell Differentiation | |
| US20230092787A1 (en) | Car t cells targeting the integrin alphav beta3 exhibit robust anti-tumor responses against gliomas and other solid tumor malignancies | |
| US20150329857A1 (en) | Rna interference to activate stem cells | |
| US20150283164A1 (en) | Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 | |
| KR20140122380A (ko) | Tctp-ptd를 포함하는 유전자 전달체 | |
| Yokota | 32. OCs induced Ki-67-negative population in leukemic cells We next sought to determine the source of growth suppression of Ba/F3 wt bcr-abl cells in the OB+ OC+ bone co-culture. First, we examined the cell cycle status of Ba/F3 wt bcr-abl cells co-cultured with OBs, OCs and/or bone slices. Ki-57 is expressed throughout |